PTGX — PROTAGONIST THERAPEUTICS INC (Healthcare >> Biotechnology)
PTGX FAQ
What is PTGX's P/E ratio?
PROTAGONIST THERAPEUTICS INC (PTGX) currently trades at a P/E ratio of 1,655.47.
What is PTGX's ROE?
PROTAGONIST THERAPEUTICS INC reports a Return on Equity (ROE) of -17.50%.
What is PTGX's dividend yield?
PROTAGONIST THERAPEUTICS INC offers a dividend yield of 0.00%.
What is PTGX's Deepscope Quality Score?
Deepscope rates PTGX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PTGX?
Deepscope's AI Timing Score for PTGX is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PTGX belong to?
PROTAGONIST THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 97.38
Price
-5.41
(-5.26%)
Day Change
|
|
|---|
PTGX Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 15) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 97.38 |
| PBV / Sector |
9.55 / 4.63
|
| Earning Per Share | -1.78 |
| PE / Sector |
1,655.47 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
-8.32 / 0.53
|
| Average 1M Daily Value |
52.84 M
|
| Average 1W Daily Value |
69.48 M
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
37% |
| Khả năng kiếm lợi nhuận |
|
52% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-06 09:09:07 |
| Symbol | PTGX |
| Name | PROTAGONIST THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 64.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6,262.64 / 8,857.28 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560
Phone: 510 474 0170
Website: https://www.protagonist-inc.com
Employees: 131
Sector: Healthcare >> Biotechnology
Description: Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google